VYVANSE

This brand name is authorized in United States. It is also authorized in Australia, Canada, Hong Kong SAR China, Israel, Japan, New Zealand, Singapore.

Active ingredients

The drug VYVANSE contains one active pharmaceutical ingredient (API):

1	Lisdexamfetamine UNII SJT761GEGS - LISDEXAMFETAMINE DIMESYLATE
	Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine, which is responsible for the drug's activity. Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity.
	Read more about Lisdexamfetamine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYVANSE Capsule / Tablet chewable	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06BA12		N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10474G, 10486X, 10492F, 11884L, 11897E, 11898F
CA	Health Products and Food Branch	02322951, 02322978, 02347156, 02347164, 02347172, 02439603, 02458071, 02490226, 02490234, 02490242, 02490250, 02490269, 02490277
HK	Department of Health Drug Office	66636, 66637, 66638
IL	מִשְׂרַד הַבְּרִיאוּת	7378, 7379, 7380
JP	医薬品医療機器総合機構	1179059M1024, 1179059M2020
NZ	Medicines and Medical Devices Safety Authority	18623, 18624, 18625
SG	Health Sciences Authority	15840P, 15841P, 15842P, 15843P, 15844P, 15845P
US	FDA, National Drug Code	59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120